Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
19
06
2019
accepted:
05
09
2019
pubmed:
29
9
2019
medline:
28
5
2020
entrez:
29
9
2019
Statut:
ppublish
Résumé
Several treatment options are currently available for the treatment of psoriasis. To explore the main associations between patients' characteristics and systemic treatments prescribed for psoriasis in a large group of patients observed in real-life clinical practice. This was a retrospective analysis of baseline data collected within the Swiss Dermatology Network for Targeted Therapies registry in Switzerland between March 2011 and December 2017. Semantic map analysis was used in order to capture the best associations between variables taking into account other covariates in the system. A total of 549 patients (mean age 46.7 ± 14.7 years) were included in the analysis. Conventional therapies such as retinoids and methotrexate were associated with no previous systemic therapies for psoriasis, a moderate quality of life (QoL) at therapy onset and older age (≥60 years). Fumaric acid derivatives were associated with mild psoriasis (psoriasis area severity index < 10) and long disease duration (≥20 years). On the other side, cyclosporine and psoralen and ultraviolet A/ultraviolet B treatments were linked to a more severe condition, including impaired QoL, hospitalization and inability to work. Regarding biological therapies, both infliximab and adalimumab were connected to the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. Etanercept, ustekinumab and secukinumab were all connected to a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education. The analysis shows multifaceted associations between patients' characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, our semantic map indicates that comorbidities play a central role in decision-making of systemic treatments usage for psoriasis. Future studies should further investigate specific connections emerging from our data.
Sections du résumé
BACKGROUND
BACKGROUND
Several treatment options are currently available for the treatment of psoriasis.
OBJECTIVE
OBJECTIVE
To explore the main associations between patients' characteristics and systemic treatments prescribed for psoriasis in a large group of patients observed in real-life clinical practice.
METHODS
METHODS
This was a retrospective analysis of baseline data collected within the Swiss Dermatology Network for Targeted Therapies registry in Switzerland between March 2011 and December 2017. Semantic map analysis was used in order to capture the best associations between variables taking into account other covariates in the system.
RESULTS
RESULTS
A total of 549 patients (mean age 46.7 ± 14.7 years) were included in the analysis. Conventional therapies such as retinoids and methotrexate were associated with no previous systemic therapies for psoriasis, a moderate quality of life (QoL) at therapy onset and older age (≥60 years). Fumaric acid derivatives were associated with mild psoriasis (psoriasis area severity index < 10) and long disease duration (≥20 years). On the other side, cyclosporine and psoralen and ultraviolet A/ultraviolet B treatments were linked to a more severe condition, including impaired QoL, hospitalization and inability to work. Regarding biological therapies, both infliximab and adalimumab were connected to the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. Etanercept, ustekinumab and secukinumab were all connected to a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education.
CONCLUSIONS
CONCLUSIONS
The analysis shows multifaceted associations between patients' characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, our semantic map indicates that comorbidities play a central role in decision-making of systemic treatments usage for psoriasis. Future studies should further investigate specific connections emerging from our data.
Substances chimiques
Dermatologic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2313-2318Subventions
Organisme : Janssen
Organisme : AbbVie
Organisme : Celgene
Organisme : Lilly
Organisme : Novartis
Organisme : Pfizer
Informations de copyright
© 2019 European Academy of Dermatology and Venereology.
Références
Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006; 212: 327-337.
Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004; 208: 38-42.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
Basko-Plluska JL, Petronic-Rosic V. Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis 2012; 2: 67-76.
Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164(Suppl 1): 1-14.
Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377-390.
Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015; 33: 41-55.
Nast A, Gisondi P, Ormerod AD et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294.
Garcia-Doval I, Rustenbach SJ, Stern R et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 2013; 169: 710-714.
Kolios AG, Yawalkar N, Anliker M et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology 2016; 232: 385-406.
Ighani A, Partridge ACR, Shear NH et al. Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents. J Cutan Med Surg 2019; 23: 204-221.
Jungo P, Maul JT, Djamei V et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a Swiss real-life psoriasis registry. Dermatology 2016; 232: 655-663.
Maul JT, Djamei V, Kolios AGA et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology 2016; 232: 640-647.
Cazzaniga S, Apfelbacher C, Diepgen T et al. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. Br J Dermatol 2018; 178: 229-237.
Cazzaniga S, Naldi L, Virgili A et al. An original exploration of genital lichen sclerosus: the semantic connectivity map. J Eur Acad Dermatol Venereol 2019; 33: e59-e62.
Pemmaraju S, Skiena S. Combinatorics and graph theory in mathematica. In: Pemmaraju S, Skiena S, ed. Computational Discrete Mathematics. Cambridge University Press, Cambridge, 2003: 336-337.
Davila-Seijo P, Garcia-Doval I, Naldi L et al. Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: evidence from the PSONET registries. Acta Derm Venereol 2017; 97: 516-518.
Naldi L, Cazzaniga S, Di Mercurio M, Grossi E, Addis A. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. Br J Dermatol 2017; 176: 1331-1338.
Dickel H, Bruckner T, Altmeyer P. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. J Eur Acad Dermatol Venereol 2018; 32: 1710-1727.
Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol 2016; 15: 293-301.
Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 2013; 14: 87-109.
Rodgers M, Epstein D, Bojke L et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011; 15: i-xxi, 1-329.
Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ 2013; 16: 479-489.
Rossi RE, Parisi I, Despott EJ et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol 2014; 20: 17352-17359.
Papp KA, Poulin Y, Bissonnette R et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66: e33-e45.
Tabolli S, Paradisi A, Giannantoni P, Gubinelli E, Abeni D. Factors associated with the prescription of “traditional” or “biological” systemic treatment in psoriasis. J Dermatolog Treat 2015; 26: 37-40.
Costanzo A, Bianchi L, Flori ML et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179: 1072-1080.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27-40.